References: Dugani SB, Moorthy MV, Li C, et al
[xv] - Garcia-Giralt E, Perdereau B, Brixy F, et al
Moira Kapral is supported by the Sir John and Lady Eaton Chair from the Department of Medicine, Temerty Faculty of Medicine, University of Toronto
www.provepharm.com About Daiichi Sankyo Group Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose "to contribute to the enrichment of quality of life around the world." In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs
As a result, GLP-1(936) reduces the number of granules available for exocytosis in -cells, thereby decreasing the release of glucagon